

An academic organisation perspective on complex clinical trials: the EORTC experience

Saskia Litière EORTC, Head of statistics department 23/11/2023

ACT EU Multi-Stakeholder Workshop on Methodology Guidance: A patientcentred approach to methodology


The future of cancer therapy

Classified as public by the European Medicines Agency




Examples

UPSTREAM One platform, one disease, multiple cohorts



Oligocare

Observational study, randomized cohort (TWICS)



https://project.eortc.org/e2-radiate/

EUDRACT 2017-000086-74, NCT03088059

Some observations

Upstream

- No adjustment for multiple testing
 - Separate trials ...
- Practically:
 - One study number
 - One (big) protocol
 - One database
 - similar structure for programming and analysis
 - becomes quite complex (~amendments)
 - well understood by sites?
- Separate parts submitted as one clinical trial with subprotocols
 - = amendment nightmare

Would be done differently if we had to restart today

Oligocare

- Observational study so slightly different approach (<> CTIS "needs")
- Practically:
 - Several study numbers
 - Several protocols
 - One database
- So far seems to work quite well
- To embed a randomized question (XXX vs SOC) -> TWICs
 - <u>https://www.twics.global/</u>
 - Staged consent -> not generally accepted (yet?) by ECs
 - Could need to be written as CTR protocol (~XXX)
 - Separate protocol linked to a master protocol in CTIS?